Laurence Reid and Brad Crutchfield appointed to Broken Strings’ board of directors
Natalia Elliot | September 25, 2024 | Appointment | | Broken String Biosciences, Corporate
Cambridge, UK-based genomics company Broken String Biosciences has announced the appointment of Laurence Reid PhD as chairman, and Brad Crutchfield as non-executive director (NED), to its board of directors.
Laurence Reid is a seasoned biotech entrepreneur who was previously CEO at Decibel Therapeutics and Warp Drive Bio, and held C-suite positions at Alnylam Pharma, Ensemble Discovery and Millennium Pharma. He also served as entrepreneur-in-residence at Third Rock Ventures, focusing on novel drug discovery and development opportunities. Laurence now serves on multiple boards for biotech companies.
Brad Crutchfield recently served as chief commercial officer of 10x Genomics, as well as held several leadership positions including senior vice president of Life Sciences at QIAGEN; vice president and general manager, EMEA at Illumina; and president of the Life Science Group at Bio-Rad Laboratories. Brad currently sits of the boards of Pixelgen AB, Partillion, and S2 Genomics, as well as serving as senior advisor for Alamar Biosciences.
Laurence Reid PhD, chair of the Board, Broken String Biosciences, commented: “The promise of therapies based on genome editing is fundamentally linked to understanding the desired genome modifications relative to the undesired modifications. INDUCE-seq is an extremely promising technology that will enable therapeutic developers to bring their cutting-edge treatments to market with a new standard of precision. I’m pleased to be joining the company and eager to work closely with the leadership team to develop a comprehensive commercial strategy and support the company in its ongoing growth.”
Brad Crutchfield, non-executive director at Broken String Biosciences, commented: “Cell and gene therapies hold immense promise for transforming disease treatment, and Broken String’s solution will be instrumental in helping companies accelerate and de-risk their drug development pipelines. By enabling the development of these next-generation therapies with precision and safety, we can enhance enterprise value for pharma and biotech firms. I look forward to leveraging my experience in bringing innovative life science tools to market to help position the company’s offerings for success in this rapidly evolving field.”
James Spargo
Related Content
Broken String Biosciences and the Francis Crick Institute collaborate on ALS research
Genomics company Broken String Biosciences and biomedical discovery institute Francis Crick have announced a research …
